This 2003 practice guideline published in Circulation (DOI: 10.1161/01.cir.0000052939.59093.45) by the CDC and AHA evaluates the clinical relevance of inflammatory markers, particularly high-sensitivity C-reactive protein (hs-CRP), in assessing cardiovascular disease (CVD) risk. It concludes that hs-CRP is a useful tool for identifying low-grade systemic inflammation and may enhance cardiovascular risk